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AMI onset to revascularization 3.95 hours; primary fatlure 0.7 %. The primary clinical 
endpoint data appear in the table. Multivariate analysis showed abciximab as indspen- 
dently related to l-month outcome (HR 0.41; 95% Cl 0.17-0.97, p=O.O41). 
Abciximab Stent Alone p value 
n=200 n=200 
Death 7 (3.5%) a (4%) 0.792 
Reinfarction 1 (0.5%) 9 (4.5%) 0.010 
TVR 1 (0.5%) 3 (1.5%) 0.315 
Stroke 0 1 (0.5%) 0.317 
MACCE 9 (4.5%) 21 (10.5%) 0.023 
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Improved Clinical Outcomes With Abciximab Therapy in 
Acute Myocardlal Infarction: A Systematic Overview of 
Randomized Clinical Trials 
David E. Kandzari, Vie Hasselblad, James E. Tcheng, Gregg W. Stone, Robert M. Califf, 
Sorin J. Brewer. Gilles Montalescot. Franz-Josef Neumann, Adnan Kastrati, Robert A. 
Harrington. Duke Clintcal Research Institute, Durham, NC 
Background- Investigations examining glycoprotein (GP) Ilb/llla inhibition in primary 
percutaneous coronary intervention (PCI) have suggested the efficacy of abciximab in 
improvtng early clinical and angiographic outcomes, yet sample size limitations and vari- 
ability in trial design precluded the results from any individual study from being definitive. 
Methods-We identified 4 randomized trials of primary PCI for acute ST-elevation myo- 
cardial infarction (Ml) (ADMIRAL, CADILLAC, ISAR-2, RAPPORT) with the followtng 
characteristics: comparison of GP llbillla antagonists with placebo or control therapy; 
enrollment of ~200 pts; and description of a 30.day clinical endpoint that included the 
variables of death (D), repeat Ml (reMI), and urgent target vessel revascularization 
(TVR). The primary efficacy endpoint was a composite of D. reMI, or ischemia-driven 
TVR at 30 days. 
Results-Among 3,266 pts with MI, there were no stgnificant differences between patients 
randomized to abciximab (n=l643) or those assigned to placebo or control (n=1623). 
Thirty day clinical events are summarized. 
30-day Clinical Outcome Odds Ratio (95% Cl) 
Death 0.73 (0.46, 1.16) 
ReMl 0.72 (0.39, 1.34) 
Ischemra-dnvenTVR 0.46 (0.30, 0.70) 
Death or reMl 0.72 (0.49, 1.05) 
Death, reMI, or ischemia-driven NR 0.54 (0.40, 0.72) 
Conclusions-In this first systematic overview of clinical trials evaluating early outcomes 
with GP Ilb/llla inhibition in primary PCI, abciximab was associated with significant 
reductions in the 30.day composite endpoint of D, reMI, and ischemic NR and a trend 
toward reductions in 30.day D or reMI. These findings strongly encourage the use of 
intravenous GP llblllla inhibition as adjunctive therapy in primary PCI. 
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1025MP-167 Effect of Abciximab on Myocardial Microcirculation 
After Successful Primary Percutaneous Coronary 
Intervention for Acute ST-Segment Elevation 
Myocardial Infarction 
Stephanie Lehrke, Henning Steen, Ralph Toelg. Uwe K. Wiegand, Evangelos Giannitsis, 
Huoo A. Katus. Medizinische Universitaetsklinik Heidelbero. Heidelbera. Germanv. -. 
Medizinische Universitaet zu Luebeck, Luebeck, Germany 
Background: Reports on the beneficial role of adjunctive therapy with GPllb/llla inhibitors 
in pts. treated successfully with primary percutaneous coronary intervention (PCI) for 
acute ST-segment elevation myocardial infarction (STEMI) are inconsistent. We sought 
to determine whether and in which subgroups of these pts abciximab improves microvas- 
cular perfusion. 
Methods: We included 145 pts with acute STEMI in whom epicardial perfusion (TIMI 
grade 3 flow, resrdual stenosis ~30%) was restored successfully with primary PCI. 57/ 
145 pts (39%) received the GPllb/llfa inhibitor abciximab. Serum concentrations of car- 
diac troponin T (cTnT) were measured lust prior to reperfusion (TO) and 60 minutes 
thereafter (T60). The TGOiTO ratio was used to estimate tissue-level perfusion, a high 
T60ITO ratio suggesttng a good mtcrovascular perfusion.On basis of TOrTGO ratio, pts 
were divided into quartiles with median T60ITO ratios of 2.03, 6.66,24.61 and 134.5 
respectively. The percentage of pts within the three upper quartiles was compared 
between the two treatment groups. Analysis was done for the entire study population and 
for prespecified subgroups according to age (cut-off 70 yrs.), gender, cTnT status on 
admission (cut-off O.lpglL), time from symptom onset to admission (cut-off 6 h(s), and 
diabetes mellitus 
Results: Both treatment groups compared favourably with respect to basekne clinical 
characteristics. The percentage of pts who obtained T6OiTO ratios within the three upper 
quartiles was significantly higher after administration of abciximab suggesting rmproved 
microvascular perfusion (86% vs. 69%, p=O.O5). Among the prespecified subgroups 
abciximab significantly improved microcirculation in pts with an admission cTnT 20.1 pglL 
(p= 0.04) in males (p=O.O2) and in pts > 70 yrs of age (p=O.Ol).No benficial effect could 
be seen in women, in pts with an admission cTnT <O.Olug/L and in pts < 70 yrs of age. 
Conclusions: Abciximab improves microvascular perfusion in STEMI after successful re- 
establishment of epicardial flow by primary PCI. The treatment benefit seems to be espe- 
cially pronounced in particular subgroups. 
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1025MP-168 Reduction of Hospital Mortality in Patients With ST 
Elevation Myocardial Infarction Receiving Glycoprotein 
llb/llla Antagonists: Results of the ACOS Registry 
Anselm K. Gitt, Rudolf Schiele. Steffen Schneider, Harm Wienbergen. Tobias Heer, 
Martin G. Gottwik. Jochen Senaes. ACOS-Studv-Grow. Herzzentrum Ludwiashafen _ _ 
Ludwigshafen, Germany, Klinikum Nuernberg Sued, Nuernberg. Germany 
Background: The beneficial effect of IlbIllla-recpetor antagonists (Ilb/llla) has been 
proven in randomised trials on acute coronary syndromes (ACS). Little data exist on the 
frequency of Ilb/llla use and its influence on outcome of patients with acute ST-elevation 
myocardial infarction (STEMI) in clinical practice. 
Methods: Since June 2000 consecutive patients (pts) with ACS have been enrolled into 
the ACOS-Registry (Acute Coronary Syndrome, 154 hospitals) in Germany. We analy- 
sed the prospective data of STEMI-pts with and without treatment wth Ilb/llla to identify 
the impact of this treatment on hospital outcome. 
Results: Out of 12,61 I consecutive pts with ACS, 5,971 (47%) presented with STEMI. 
2,259 of these pts (37%) were treated with Ilb/llla. Determinants for the use of Ilb/llla in 
STEMI were prehospital delay < 4 hours (OR 1.24, 1.05-l .46) and the performance of 
primary PCI (OR 4.06, 3.12-5.34). Prior STEMI or concomitant diseases, especially dia- 
betes did not influence the decision. STEMI pts treated with Ilb/llla were younger and 
already had received prior PCI more often than pts who were not treated with Ilblllla. 
After adjusting for differences in baseline characteristics and acute reperfusion therapy, 
the use of Ilb/llla in STEMI pts was associated with a 24% reduction of hospital mortality 
(OR 0.76,0.62-0.94). 
Conclusion: The use of Ilb/llla in acute STEMI was associated with an additional 24% 
reduction of hospital mortality independent of acute repelfusion therapy. 
Age (years) 
Prior PCI 
Hypercholesteremia 
Diabetes 
PCI 
Stent (relative to PCI) 
Hospital mortality 
STEMI with Ilb/flla STEMI without Ilb/llfa p 
63 66 <O.Ol 
6.2 % 5,3 % co.01 
461 % 42.6 % <O.Ol 
216% 269 % co.01 
60,O % 22,9 % <O.Ol 
81,6% 74,6 % so.01 
6,2 % 11,2% <O.Ol 
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1025MP-169 Outcomes in Patients Requiring Bail-Out Abciximab 
During Primary Intervention in Acute Myocardial 
Infarction: Analysis From the CADILLAC Trial 
Dale T. Ashby, James E. Tcheng, Cindy L. Grines, David A. Cox. Roxana Mehran. Marlin 
P. Fahy, Eulogio Garcia, John J. Griffin, Giulio Guagliumi, Thomas D. Stuckey. Mark 
Turco, Alexandra J. Lansky, Gregg W. Stone, Cardiovascular Research Foundation, 
New York, NY, CADILLAC Investigators 
Eackgrounrt As an adjunct to PCI, glycoprotein Ilb/llla receptor inhibitors may either be 
used prophylactically in all patients or selectively in a bail-out fashion if procedural com- 
plications occur after PCI. The fate of patients requiring bail-out llblllla inhibitors during 
primary PCI for AMI is unknown. 
Methods In the CADILLAC Trial 2,062 patients of any age with AMI within 12 hours of 
symptom onset were randomized to undergo PTCA alone, PTCA plus abciximab (abcx), 
stenting alone or stenting plus abcx. Patients assigned to “no abcx” were permitted to 
cross-over and receive abcx for persistent thrombus, dissection, distal emboli or subopti- 
mal epicardial blood flow refractory to tntra-arterial calcium blockers. 
Results Of 1,030 patients assigned to no abcx, 62 (6.0%) crossed over and were 
administered abcx. 30 day outcomes appear in the Table. 
Conclusiolr Patients not administered up-front llblllla inhibitors in whom atxx is 
required for procedural complications or a suboptimal result have markedly worse proce- 
dural results, more bleeding and greater rates of major adverse cardiac events than 
patients routinely treated with abcx upfront. These data suggest that the proper way to 
use abcx is prophylactically, and conversely question the utility of abcx rn a bail-out appli- 
cation during AMI intervention. 
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TABLE 
Procedure Time (hrs) 
Procedure Sucess (%) 
Post-Procedural TIMI 
3 flow (“/n) 
30 Day Events 
Death (%) 
Reinfarction (%) 
Disabling Stroke (%) 
lschsmic TVR (%) 
MACE (%) 
Any TVR (%) 
Moderate/Severe 
Bleed (%) 
Blood Transfusion (%) 
b 
(n=966) 
1 .Ol 
Crossed-Over to 
Abciximab 
(n=62) 
Routine 
Abciximab 
(nz1052) 
1.62 1 .oo 
90.7 60.4 93.5 
96.1 70.0 96.5 
2.3 1.6 
0.6 
0.1 
1.7 
1.7 
1.9 
0.8 
0.1 
4.2 
6.7 
4.5 
6.3 
11.5 
6.3 
13.2 
2.5 
4.6 0.01 
2.6 0.01 
3.2 3.0 
3.3 12.9 5.0 
P 
Value 
co.ooo 
1 
<o.OQo 
1 
<o.ooO 
1 
NS 
NS 
0.006 
0.01 
<o.cOo 
1 
0.0006 
1:24 p.m. 
1025MP-170 Opening the Window of Facilitated Percutaneous 
Coronary Intervention in Acute Infarction: The Role of 
Combined llblllla Inhibition and Thrombolytic Therapy 
Mitchell W. Krucoff , Cynthia L. Green. Per Johanson, Suzanne W. Crater, Matthew T. Pisra Anaelica Msrlini. Diego Ardissino, Annamaria Andreoli, Silvio Ricci, Alessandra 
Roe, Anatoly Langer, Robert P. Giugliano, A. Michael Lincoff. Robert A. Harrington, Eric Rep&to, Alessandro Lombardi, Ospedale Niguarda. Milan, Italy, Ospedale Maggiors, 
J. Topol, Robert M. Califf, Duke University Medical Center, Durham, NC Parma, Italy 
Background: Combined llbllla inhibition and lytic therapy have not shown mortality bsn- 
efit vs. lytics alone. however key trials have not used PCI. Restored infarct artery flow 
prior to PCI might facilitate instrumentation, salvage and outcome. 
Methods: The timing of reperfusion (as minutes from the onset of lytic therapy) based on 
>50% ST-segment recovery analyzed from continuous digital 12-lead monitoring ana- 
lyzed in blinded core laboratory was aggregated over 30 minute intervals for all 654 pts. 
from 4 trials (IMPACT-AMI, PARADIGM, GUSTO-V, INTEGRITI) combining lamifiban, 
sptifibatide and abciximab with lytics (COMBO) vs. standard lytics (STD) in patients with 
acute ST elevation Ml. 
Results: (as % of pts. with ST recovery up to the time interval) 
Time (min) 30 60 90 120 180 240 
COMBO, % 37.4 56.7 72.7 79.5 86.6 69.2 
STD. % 33.6 46.0 63.6 72.9 80.6 66.5 
pvalue .34 .03 .02 .06 .04 .30 
Conclusions: While in large trials combined llbllla inhibition and lytic therapy doss not 
convey mortality benefit as lone medical therapy vs. standard lytic therapy, continuous 
12.lead ST recovery data suggest a significantly accelerated early phase of rsperfusion 
beginning 30-60 minutes from treatment and widening over the first 2-3 hours. This 
potentially opens a temporal and technical “window” of opportunity for PCI instrumenta- 
tion in a more stable patient with better distal vessel visualization, which overall might 
improve myocardial salvage and clinical outcomes as a true facilitated PCI strategy. 
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Enoxaparin Is Superior to Unfractionated tleparin After 
Fibrinolysis in Acute Myocardial Infarction: Meta- 
Analysis of ASSENT-3, HART-II, and ENTIRE-TIMl-23 
Trials 
Peter R. Sinnaeve. Elliott M. Antman. Allan M. Ross, Victor Hasselblad, Frans J. Van de 
Wert. Christopher 8. Granger, Duke Clinical Research Institute, Durham, NC, University 
Hospital Gasthuisberg, Leuven, Belgium 
Background ASSENT-3 found that enoxaparin resulted I” lower rates of death, reMI, 
and refractory ischemia than unfractionatsd heparin (UFH). The HART-II and ENTIRE- 
TIMI 23 trials focused on angiographic endpoints with early angiography in all patients. In 
order to combine all available randomized data of snoxaparin vs. UFH following full-dose 
thrombolysis and to include more patients undergoing early angiography, we performed 
a meta-analysis of these trials. 
Methods and results805 patients in the combined dataset underwent urgent angiogra- 
phy on the day of admission. We focused on death, rsinfarction (reMI), and refractory 
ischsmia at 30 days in all trials, and major bleeding. Me&analysis was performed with a 
random effects model. Results are summarized in Table 1. Patients treated with enox- 
aparin had fewer ischsmic complications than with UFH, as demonstrated by a 20% rela- 
tive risk reduction in the triple endpoint. Death was non-statisbcally significantly 
decreased (OR 0.88, 95%CI 0.68-l .14). 
Conclusion Enoxaparin is superior to UFH I” reducing ischemic complications in 
patients with acute MI treated with fibrinolysis, without substantially increasing major 
bleeding even with frequent use of urgent angiography. 
Table I 
Enoxa~adnvsUFH Dsath/ReMl/ 
Refractory 
lschsmia OR 
(95%CI) 
ASSENT-3 0.81 (0.68-0.95) 
(rl=4078) 
ENTIRE (n=242) 0.38 (0.19-0.79) 
HART-II (n=400) 1.21 (0.70-2.10) 
Total 0.80 (0.68-0.95) 
(n=4717) 
Death/ReMI OR Major bleeding 
(95%CI) OR (95%CI) 
0.86 (0.70-l .05) 1.42 (0.96. 
2.01) 
0.24 (0.09-0.62) 0.76 (0.16- 
4.58) 
1 .OO (0.49-2.06) 1.18 (0.39. 
3.57) 
0.74 (0.51-l .09) 1.34 (0.93. 
1.95) 
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1025MP-172 Coagulation Activation Induced by Fibrinolytic Therapy 
Is Blunted by the Combination of a Low-Dose 
Fibrinolytic and a Platelet Glycoprotein Ilb/llla Inhibitor: 
The GUSTO V Italian Hematologic Substudy 
Background: Fibrinolysis in acute myocardial infarction activates blood coagulation and 
may favour reocclusion or ischemic complications. The aim of the GUSTO V Italian 
Hem&logic Substudy was to compare the effects of full-dose retsplase versus half doss 
rsteplass combined with full doss abciximab on the markers of coagulation activation 
soon after myocardial infarction. 
Methods and results: We measured the plasma lsvsl~ of prothrombin fragment I+2 
(F1+2, a marker of prothrombin sctlvation) and the thrombinlantithrombin complex (TAT, 
a marker of thrombin generation) in 67 patients participating in the GUSTO V study who 
were random&d to receive full-dose rstsplase (34 patients) or the combination of half- 
doss reteplase and full-dose abclximab (33 patients), in addition to hepann. Blood sam- 
ples were obtained at baseline, and after 90 minutes and 24 hours. There was no diffsr- 
snce in the baseline plasma levels of F1+2 or TAT between the two groups. Median 
Fl c2 levels at 90 minutes were significantly lower In the patients receiving combination 
therapy than In those rsceivlng retsplase alone (2.0 vs 3.2 nmol/L; P=O.O06), the median 
Increase being significantly greater in the latter (P=O.O07); the same was true in the case 
of median 90-minute TAT levels (6.7 vs 7.9 rig/L;; P=O.O16), with a significantly higher 
median increase in the patients receiving rstsplass alone (P=O.O05). There was no 
between-group difference in the plasma levels of either F1+2 or TAT after 24 hours. Con- 
clusion: In patients with acute myocardial infarction, the combination of half-dose 
rsteplass and full-dose abciximab blunts the increase in prothrombin activation and 
thiombin generation observed with full-doss retsplase. 
